Rapidemic
Leiden · Founded 2020
About Rapidemic
Rapidemic develops a molecular point-of-care test for the diagnosis of sexually transmitted infections. Their proprietary technology increases the sensitivity and specificity of the reaction while keeping manipulations to a minimum. Its technology enables low-temperature diagnostics while safeguarding accuracy and reducing false positives.
Company Facts
- Founded: 2020
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.9M
- Funding stage: Seed
- Last round: Grant (Sep 2025)
- Website: https://rapidemic.com
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical, Product Research
Social Profiles
Canonical: https://fsome.com/organization/rapidemic-60305 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.